Frankfurt
17.08.26 | 08:07
0,143 Euro
+2,44 % +0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:30 | 2cureX AB - Removal from trading on Nasdaq First North Growth Market | 144 | GlobeNewswire | According to item 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to item 8.2.7 of the Nasdaq First North... ► Artikel lesen | |
| 06.07. | The observation status for 2cureX is updated | 426 | GlobeNewswire | On February 27, 2026, the shares in Insplorion AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position.
On July 6, 2026... ► Artikel lesen | |
| 2CUREX Aktie jetzt für 0€ handeln | |||||
| 06.07. | 2cureX AB: 2cureX AB accelerates reintegration of operating business into the listed company | 308 | GlobeNewswire (Europe) | 2cureX AB (publ) ("2cureX" or the "Company") today announces that it has submitted comprehensive documentation to Nasdaq Stockholm demonstrating the Company's ongoing commercial activities, operational... ► Artikel lesen | |
| 25.06. | 2curex AB: Communiqué From The Annual General Meeting On Thursday 25 June 2026 In 2curex Ab | 220 | GlobeNewswire (Europe) | N.B. The English text is an unofficial translation. Today, 25 June 2026, the Annual General Meeting (the "AGM") of 2cureX AB, reg. no. 559128-0077, was held. Below is a summary of the resolutions passed.... ► Artikel lesen | |
| 20.05. | 2cureX AB: 2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor | 238 | GlobeNewswire (Europe) | 2cureX AB today announces the signing of a strategic services and collaboration agreement with StoreMyTumor, a US-based oncology logistics and tumour preservation platform operating under AAA Health... ► Artikel lesen | |
| 22.04. | 2cureX AB: 2cureX AB completes oversubscribed directed issue | 237 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") today announces that it has successfully completed an oversubscribed directed share issue of 6,800,000 shares to a select group of international investors (the... ► Artikel lesen | |
| 27.02. | 2cureX AB receives observation status | 263 | GlobeNewswire | Yesterday, February 26, 2026, 2cureX AB (the "Company") disclosed its annual financial statement release for 2025 with information on the Company's financial situation.
According to item 6.3.1... ► Artikel lesen | |
| 26.02. | 2cureX AB: 2cureX AB (publ) publishes Interim Report for the Second Half of 2025 | 264 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") hereby publishes its interim report for the second half of 2025 (July 1 - December 31, 2025).
The second half of 2025 has been characterised by continued execution... ► Artikel lesen | |
| 21.08.25 | 2cureX AB: 2cureX AB (";2cureX") hereby publishes the interim report for the first half year of 2025. | 406 | GlobeNewswire (Europe) | The interim report is available as an attached document as well as on the company's website (https://www.2curex.se). A short summary of the report follows below.
CEO Nat Hutley comments:"EXECUTION.... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,005 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| EPIGENOMICS | 0,910 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| BIOFRONTERA | 2,350 | -2,08 % | Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation | ||
| NANOREPRO | 1,890 | -1,82 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.08.2026 / 07:15... ► Artikel lesen | |
| BIOXXMED | 1,000 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 1,186 | +1,89 % | Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen | ||
| CLINUVEL | 5,998 | -0,03 % | CLINUVEL PHARMACEUTICALS LIMITED: Becoming a substantial holder | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,570 | -0,11 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| EDITAS MEDICINE | 2,450 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,720 | +0,38 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| IBIO | 1,303 | +5,00 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ASEP MEDICAL | 0,070 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| MYRIAD GENETICS | 2,643 | +0,72 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen |
2CUREX AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,44 % bei einem Aktienkurs von 0,143 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 2CUREX AB finden Sie auf Wallstreet Online.